





Myostatin and Activin A Bispecific



Combined Myostatin and Activin A Antagonism Precision Bispecific Approach to Address Root Drivers of PH-HFpEF*



Targeting the Core Biology of Disease Across Multiple Organs

- Our bispecific antibody is designed to selectively neutralize what are believed to be key pathological ligands:
 - **Activin A** → cardiac fibrosis and vascular remodeling¹
 - **Myostatin/GDF11** → skeletal muscle dysfunction and exercise intolerance^{2,3}
- Together, these pathways address two major biological drivers of PH-HFpEF.

Selective Modulation Rather Than Broad Pathway Blockade⁴

- Our bispecific antibody is constructed from first principles to achieve intentional selectivity
- Intentionally spares related signaling molecules maintaining physiologic balance
- Focused on disease-driving biology


Platform-Enabled Precision Engineering

- Mammalian display platform allows rapid generation of highly selective multispecific antibodies
- Design strategy enabled by iBio's experience in the TGF- β superfamily


Strategic Value

- A differentiated, multi-organ therapeutic approach in a clinically validated pathway with strong partnering potential.





Binding of Myostatin and Activin A to cells leads to **muscle atrophy**




Simultaneous blocking of Myostatin and Activin A leads to **muscle growth**




GDF8, GDF11, and Activin A Promote Fibrotic Activation of Cardiac Fibroblasts



iBio's Myostatin and Activin A Bispecific: Combined, Antibody-Mediated Blockade of GDF8/GDF11/Activin A



INCREASED MUSCLE FUSION INDEX IN HUMAN MUSCLE STEM CELLS IS A SURROGATE OF MUSCLE GROWTH



IMPROVEMENT IN STRESS-INDUCED RIGHT VENTRICULAR REMODELING

Mouse Model of HFpEF

- Diet-induced obesity
- Induced hemodynamic stress

